348 related articles for article (PubMed ID: 29896665)
41. [Antiherpetic chemotherapy].
Shiraki K; Kurokawa M
Nihon Rinsho; 2000 Apr; 58(4):939-43. PubMed ID: 10774220
[TBL] [Abstract][Full Text] [Related]
42. The pharmacokinetic basis of oral valacyclovir treatment of herpes simplex virus (HSV) or varicella zoster virus (VZV) meningitis, meningoencephalitis or encephalitis in adults.
Cunha BA; Baron J
J Chemother; 2017 Apr; 29(2):122-125. PubMed ID: 26239190
[No Abstract] [Full Text] [Related]
43. Synergistic activity of amenamevir (ASP2151) with nucleoside analogs against herpes simplex virus types 1 and 2 and varicella-zoster virus.
Chono K; Katsumata K; Suzuki H; Shiraki K
Antiviral Res; 2013 Feb; 97(2):154-60. PubMed ID: 23261844
[TBL] [Abstract][Full Text] [Related]
44. Helicase-primase inhibitors from Medshine Discovery Inc. (WO2018/127207 and WO2020/007355) for the treatment of herpes simplex virus infections - structure proposal for Phaeno Therapeutics drug candidate HN0037.
Gege C; Kleymann G
Expert Opin Ther Pat; 2022 Sep; 32(9):933-937. PubMed ID: 35965439
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of amenamevir for the treatment of herpes zoster in an immunocompromised patient: Report of a case.
Ishiguro A; Takama H; Yanagishita T; Ohshima Y; Watanabe D
J Dermatol; 2019 Aug; 46(8):e270-e271. PubMed ID: 30897230
[No Abstract] [Full Text] [Related]
46. Update on emerging antivirals for the management of herpes simplex virus infections: a patenting perspective.
Vadlapudi AD; Vadlapatla RK; Mitra AK
Recent Pat Antiinfect Drug Discov; 2013 Apr; 8(1):55-67. PubMed ID: 23331181
[TBL] [Abstract][Full Text] [Related]
47. Inhibitory effect of amenamevir on acute herpetic pain and postherpetic neuralgia in mice infected with herpes simplex virus-1.
Ueda Y; Uta D; Tanbo S; Kawabata A; Kanayama S; Osaki M; Nozawa N; Matsumoto T; Andoh T
J Dermatol Sci; 2020 Apr; 98(1):50-57. PubMed ID: 32284168
[TBL] [Abstract][Full Text] [Related]
48. [Chemotherapy to thymidine kinase producing virus (HSV-1, HSV-2, VZV) infection].
Goto H; Shimada K
Nihon Rinsho; 1989 Feb; 47(2):378-83. PubMed ID: 2542661
[No Abstract] [Full Text] [Related]
49. Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster.
Shoji N; Tanese K; Sasaki A; Horiuchi T; Utsuno Y; Fukuda K; Hoshino Y; Noda S; Minami H; Asakura W;
J Dermatol; 2020 Jul; 47(7):683-688. PubMed ID: 32424854
[TBL] [Abstract][Full Text] [Related]
50. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
[TBL] [Abstract][Full Text] [Related]
51. Susceptibility of herpes simplex virus isolated from genital herpes lesions to ASP2151, a novel helicase-primase inhibitor.
Katsumata K; Weinberg A; Chono K; Takakura S; Kontani T; Suzuki H
Antimicrob Agents Chemother; 2012 Jul; 56(7):3587-91. PubMed ID: 22526302
[TBL] [Abstract][Full Text] [Related]
52. Successful treatment with famciclovir for varicella zoster virus infection resistant to acyclovir.
Oka T; Hishizawa M; Yamashita K; Shiraki K; Takaori-Kondo A
J Infect Chemother; 2021 May; 27(5):755-758. PubMed ID: 33358593
[TBL] [Abstract][Full Text] [Related]
53. Emergence of resistance to acyclovir and penciclovir in varicella-zoster virus and genetic analysis of acyclovir-resistant variants.
Ida M; Kageyama S; Sato H; Kamiyama T; Yamamura J; Kurokawa M; Morohashi M; Shiraki K
Antiviral Res; 1999 Jan; 40(3):155-66. PubMed ID: 10027650
[TBL] [Abstract][Full Text] [Related]
54. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
[TBL] [Abstract][Full Text] [Related]
55. The Efficacy of Amenamevir for the Treatment of Disseminated Herpes Zoster Complicated with Probable Varicella-zoster Pneumonia in an Immunocompromised Patient.
Kobayashi H; Yoshida Y; Komoshita T; Suma H; Hosokawa Y; Hirose Y; Sugimoto T; Mokuda S; Hirata S; Sugiyama E
Intern Med; 2022 Jun; 61(11):1785-1788. PubMed ID: 34776482
[TBL] [Abstract][Full Text] [Related]
56. Emerging therapies for herpes viral infections (types 1 - 8).
Chakrabarty A; Pang KR; Wu JJ; Narvaez J; Rauser M; Huang DB; Beutner KR; Tyring SK
Expert Opin Emerg Drugs; 2004 Nov; 9(2):237-56. PubMed ID: 15571482
[TBL] [Abstract][Full Text] [Related]
57. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects.
Pasternak B; Hviid A
JAMA; 2010 Aug; 304(8):859-66. PubMed ID: 20736469
[TBL] [Abstract][Full Text] [Related]
58. Current and future therapies for herpes simplex virus infections: mechanism of action and drug resistance.
James SH; Prichard MN
Curr Opin Virol; 2014 Oct; 8():54-61. PubMed ID: 25036916
[TBL] [Abstract][Full Text] [Related]
59. The helicase-primase complex as a target for effective herpesvirus antivirals.
Field HJ; Mickleburgh I
Adv Exp Med Biol; 2013; 767():145-59. PubMed ID: 23161010
[TBL] [Abstract][Full Text] [Related]
60. Profiling penciclovir susceptibility and prevalence of resistance of herpes simplex virus isolates across eleven clinical trials.
Sarisky RT; Bacon TH; Boon RJ; Duffy KE; Esser KM; Leary J; Locke LA; Nguyen TT; Quail MR; Saltzman R
Arch Virol; 2003 Sep; 148(9):1757-69. PubMed ID: 14505088
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
